Relapsed and Refractory Multiple Myeloma

Oncology
15
Pipeline Programs
5
Companies
12
Clinical Trials
3 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
3
0
1
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
3100%
+ 5 programs with unclassified modality

On Market (7)

Approved therapies currently available

U
DEXAMETHASONEApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]oral2024
U
DEXONE 0.5Approved
dexamethasone
Unknown Company
oral
U
DEXONE 0.75Approved
dexamethasone
Unknown Company
oral
U
DEXONE 1.5Approved
dexamethasone
Unknown Company
oral1975
U
DEXONE 4Approved
dexamethasone
Unknown Company
oral
U
DEXYCU KITApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]intraocular2018
U
MAXIDEXApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]ophthalmic1962

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
DexamethasonePhase 33 trials
Active Trials
NCT03029234Completed126Est. Jun 2021
NCT02939183Completed61Est. Oct 2022
NCT00925821Completed146
GS
Gilead SciencesFOSTER CITY, CA
4 programs
2
2
CYT997Phase 2
CYT997Phase 21 trial
anitocabtagene-autoleucelPhase 1Cell Therapy
anitocabtagene-autoleucelPhase 1Cell Therapy1 trial
Active Trials
NCT04155749Active Not Recruiting40Est. May 2027
NCT00664378Terminated5Est. Feb 2011
Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT05530421RecruitingEst. Mar 2030
Bristol Myers Squibb
1 program
1
MezigdomidePhase 1/25 trials
Active Trials
NCT06994117Available
NCT06050512Withdrawn0Est. Oct 2026
NCT05651932Recruiting125Est. Jun 2028
+2 more trials
Arcellx
ArcellxREDWOOD CITY, CA
1 program
1
anitocabtagene-autoleucelPhase 1Cell Therapy

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbMezigdomide
AmgenDexamethasone
Karyopharm TherapeuticsSelinexor
AmgenDexamethasone
Gilead SciencesCYT997
Bristol Myers SquibbMezigdomide
Bristol Myers SquibbMezigdomide
Bristol Myers SquibbMezigdomide
Bristol Myers SquibbMezigdomide
Gilead Sciencesanitocabtagene-autoleucel
AmgenDexamethasone

Clinical Trials (12)

Total enrollment: 1,360 patients across 12 trials

NCT05552976Bristol Myers SquibbMezigdomide

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Start: Jan 2023Est. completion: Jul 2029525 patients
Phase 3Active Not Recruiting
NCT03029234AmgenDexamethasone

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Start: Mar 2017Est. completion: Jun 2021126 patients
Phase 3Completed
NCT05530421Karyopharm TherapeuticsSelinexor

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Start: Mar 2023Est. completion: Mar 2030
Phase 2Recruiting
NCT00925821AmgenDexamethasone

Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

Start: Jun 2009146 patients
Phase 2Completed
NCT00664378Gilead SciencesCYT997

Efficacy Study of CYT997 in Multiple Myeloma

Start: Jan 2008Est. completion: Feb 20115 patients
Phase 2Terminated
NCT06050512Bristol Myers SquibbMezigdomide

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Start: Oct 2023Est. completion: Oct 20260
Phase 1/2Withdrawn
NCT02343042Bristol Myers SquibbMezigdomide

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Start: Oct 2015Est. completion: Apr 2027300 patients
Phase 1/2Recruiting
NCT05651932Bristol Myers SquibbMezigdomide

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Start: Feb 2023Est. completion: Jun 2028125 patients
Phase 1Recruiting
NCT05707390Bristol Myers SquibbMezigdomide

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Start: Feb 2023Est. completion: Sep 202332 patients
Phase 1Completed
NCT04155749Gilead Sciencesanitocabtagene-autoleucel

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Start: Dec 2019Est. completion: May 202740 patients
Phase 1Active Not Recruiting
NCT02939183AmgenDexamethasone

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Start: Jan 2017Est. completion: Oct 202261 patients
Phase 1Completed
NCT06994117Bristol Myers SquibbMezigdomide

Expanded Access for Mezigdomide

N/AAvailable

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 1,360 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)